

Neonatal lethality in transgenic mice expressing prion protein with a deletion of residues 105–125

Aimin Li¹, Heather M Christensen¹,
Leanne R Stewart¹, Kevin A Roth²,
Roberto Chiesa³ and David A Harris^{1,*}

¹Department of Cell Biology and Physiology, Washington University School of Medicine, St Louis, MO, USA, ²Department of Pathology, University of Alabama at Birmingham (UAB), Birmingham, AL, USA and ³Dulbecco Telethon Institute (DTI) and Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy

To identify sequence domains important for the neurotoxic and neuroprotective activities of the prion protein (PrP), we have engineered transgenic mice that express a form of murine PrP deleted for a conserved block of 21 amino acids (residues 105–125) in the unstructured, N-terminal tail of the protein. These mice spontaneously developed a severe neurodegenerative illness that was lethal within 1 week of birth in the absence of endogenous PrP. This phenotype was reversed in a dose-dependent fashion by coexpression of wild-type PrP, with five-fold overexpression delaying death beyond 1 year. The phenotype of Tg(PrP Δ 105–125) mice is reminiscent of, but much more severe than, those described in mice that express PrP harboring larger deletions of the N-terminus, and in mice that ectopically express Doppel, a PrP paralog, in the CNS. The dramatically increased toxicity of PrP Δ 105–125 is most consistent with a model in which this protein has greatly enhanced affinity for a hypothetical receptor that serves to transduce the toxic signal. We speculate that altered binding interactions involving the 105–125 region of PrP may also play a role in generating neurotoxic signals during prion infection.

The EMBO Journal (2007) 26, 548–558.

doi:10.1038/sj.emboj.7601507

Subject Categories: molecular biology of disease; neuroscience

Keywords: lethal; prion; neurodegeneration; transgenic

Introduction

Prion diseases, also known as transmissible spongiform encephalopathies, are fatal neurodegenerative disorders that affect humans and animals. The infectious agent (prion) that causes these diseases is composed primarily of the protein PrP^{Sc} (Prusiner, 1998; Aguzzi and Polymenidou, 2004). PrP^{Sc} is a conformationally altered isoform of a normal, cell-surface glycoprotein called PrP^C. Although a great deal of information is now available about the role of PrP^{Sc} in the disease

process, relatively little is known about the normal, physiological function of PrP^C. Attempts to deduce the function of PrP^C from the phenotypes of prion protein (PrP)-null mice have been unrewarding, as lines of these mice in which the adjacent Doppel (Dpl) gene is not artifactually upregulated display no major anatomical or developmental deficits (Büeler *et al*, 1992; Manson *et al*, 1994).

Recent evidence raises the intriguing possibility that the normal physiological activity of PrP^C is in some way required for manifestation of prion-induced neuropathology. For example, PrP^C expression is essential to render neurons in the brain susceptible to the toxic effects of PrP^{Sc} emanating from grafted brain tissue (Brandner *et al*, 1996) or from nearby astrocytes (Mallucci *et al*, 2003). In addition, scrapie neuropathology is minimal in transgenic mice that express PrP^C lacking a C-terminal, glycolipid anchor, implying that membrane attachment of PrP^C is essential for transducing a PrP^{Sc}-derived neurotoxic signal (Chesebro *et al*, 2005).

The mechanism by which PrP^C contributes to prion-induced neurotoxicity is unclear. One hypothesis is that PrP^C normally serves a neuroprotective function that is abolished or subverted by interaction with PrP^{Sc} (Harris and True, 2006). In fact, several recent experiments have uncovered a cytoprotective activity of PrP^C (Roucou and LeBlanc, 2005). PrP overexpression rescues cultured neurons, some mammalian cell lines, and yeast from several kinds of death-inducing stimuli (Kuwahara *et al*, 1999; Bounhar *et al*, 2001; Diarra-Mehrpour *et al*, 2004; Li and Harris, 2005; Roucou *et al*, 2005). Moreover, endogenous PrP has been found to protect cultured neurons against oxidative stress, and brain tissue against ischemia, hypoxia, or trauma *in vivo* (Brown *et al*, 2002; Hoshino *et al*, 2003; McLennan *et al*, 2004; Spudich *et al*, 2005). Nevertheless, how the putative neuroprotective activity of PrP^C might be altered during prion diseases to produce a neurotoxic effect remains unknown.

A compelling demonstration of two contrasting biological activities of PrP^C, one neurotoxic and the other neuroprotective, comes from analysis of transgenic mice expressing certain N-terminally truncated forms of PrP (PrP Δ 32–134 and PrP Δ 32–121, collectively referred to as PrP Δ N). These mice suffer from a fatal neurodegenerative illness characterized by massive apoptosis of cerebellar granule neurons or Purkinje cells (depending on where the transgene is expressed) (Shmerling *et al*, 1998; Flechsig *et al*, 2003). Importantly, this phenotype is observed only in *Prn-p*^{0/0} mice that do not express endogenous PrP. Coexpression of wild-type PrP, either from the endogenous *Prn-p* allele or from a second transgene, completely prevents neurodegeneration in Tg(PrP Δ N) mice. A similar phenomenon has been observed in mice that ectopically express Dpl, a PrP paralog that is structurally similar to PrP Δ N. The Dpl gene, which is normally expressed primarily in testis, is expressed ectopically in the brain of certain lines of *Prn-p*^{0/0} mice as a result of intergenic splicing events between the adjacent PrP and Dpl genes (Sakaguchi *et al*, 1996; Moore *et al*, 1999; Li *et al*, 2000;

*Corresponding author. Department of Cell Biology and Physiology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA. Tel.: +1 314 362 4690; Fax: +1 314 747 0940; E-mail: dharris@wustl.edu

Received: 7 September 2006; accepted: 17 November 2006

Rossi *et al*, 2001). These lines, as well as transgenic lines expressing elevated levels of Dpl in the brain, display a neurodegenerative phenotype that is stoichiometrically rescued by wild-type PrP (Nishida *et al*, 1999; Moore *et al*, 2001; Rossi *et al*, 2001; Anderson *et al*, 2004). Taken together with the previously cited evidence for PrP cytoprotection *in vitro*, the experiments on transgenic mice expressing PrP^ΔN and Dpl suggest that PrP^C possesses neuroprotective properties, but that deletion of specific regions of the molecule can unmask powerful neurotoxic activities.

Several considerations indicate that the central region of the PrP sequence, comprising residues 105–125 in the mouse protein (residues 106–126 in the human protein), constitutes a critical determinant of the neurotoxic and neuroprotective activities of PrP. First, it was reported in the original work by Shmerling *et al* (1998), that transgenic mice that express PrP molecules carrying N-terminal deletions up through residue 106 were normal, whereas mice expressing PrP molecules with deletions that extended to residue 121 or 134 displayed a neurodegenerative phenotype. Second, a region homologous to PrP residues 105–125 is missing in Dpl, which consists of a three-helix structure similar to that found in the C-terminal half of PrP (Mo *et al*, 2001; Luhrs *et al*, 2003). Third, it has been found that the synthetic peptide PrP106–126 is toxic when applied to cultured neurons from *Prn-p*^{+/+} but not from *Prn-p*^{0/0} mice (Forloni *et al*, 1993; Brown *et al*, 1994). Although the mechanism of this toxicity is unknown, its dependence on expression of wild-type PrP suggests some connection with the normal biological activity of PrP^C.

To test the role of residues 105–125 in the biological activity of PrP, we created transgenic mice expressing PrP molecules harboring a deletion of this 21 amino-acid region. We found that these mice displayed a dramatic neurodegenerative phenotype that resulted in lethality as early as 1 week after birth. This phenotype was reversed in a dose-dependent fashion by coexpression of wild-type PrP. Our results define a critical functional domain of PrP that determines its neurotoxic and neuroprotective activities. In addition, our data suggest a model for the normal, biological function of PrP^C, and how this function may be altered in prion diseases.

Results

Generation of transgenic mice and analysis of protein expression

For convenience, we will refer to PrP carrying a deletion of residues 105–125 as PrP^ΔCR, as the deleted region lies in the central region of the protein. The deleted segment encompasses a positively charged region along with part of the adjacent hydrophobic domain (Figure 1A). A cDNA encoding murine PrP^ΔCR was introduced into the moPrP.Xho vector (Borchelt *et al*, 1996). This vector drives transgene expression under control of a *Prn-p* promoter in a pattern similar to that of endogenous PrP, with the exception that there is no expression in cerebellar Purkinje cells (Fischer *et al*, 1996). Founder mice (designated A, B, and E) were obtained by pronuclear injection of fertilized oocytes from C57BL/6J × CBA/J parents. Initially, the founders were bred to *Prn-p*^{0/0} mice to produce offspring carrying a single copy of both the PrP^ΔCR transgene and the endogenous *Prn-p* gene.

Brain homogenates from Tg(PrP^ΔCR^{+/0})/*Prn-p*^{+/0} mice were subjected to Western blotting using anti-PrP monoclo-




Figure 1 Schematic of PrP structure highlighting the CR region, and analysis of PrP expression in Tg(ΔCR) mice. (A) Structural domains of PrP are indicated by the colored blocks: SS (yellow), signal sequence; OR (green), octapeptide repeats; TM (purple), transmembrane domain; GPI (red), GPI attachment signal. The lollipop symbols indicate positions of N-linked glycosylation. The amino-acid sequence of PrP in the central region is shown below the block diagram, with the region deleted in Tg(ΔCR) mice (residues 105–125) indicated by red letters. STE, stop-transfer effector; TM, transmembrane domain. The + symbols above the sequence indicate positively charged amino acids in the STE region. (B) Brain homogenates from mice of the A, B, or E lines that were hemizygous for the PrP^ΔCR transgene on the *Prn-p*^{+/0} background, or from non-transgenic *Prn-p*^{+/0} mice were analyzed by Western blotting using anti-PrP antibody 8H4. Samples in lanes 2, 4, 6, 8, 10, and 12 were enzymatically deglycosylated with PNGase F before blotting. The positions of wild-type PrP (arrowhead) and PrP^ΔCR (arrow) are indicated. Molecular size markers are given in kDa.

nal antibody 8H4 following enzymatic deglycosylation with PNGase. PrP^ΔCR could then be distinguished from full-length, endogenous PrP owing to the small size difference (~2 kDa) between the two polypeptide chains in the absence of N-linked oligosaccharides (Figure 1B). By quantitating the relative amounts of the two bands, we determined that the expression level of PrP^ΔCR in the A and E lines was similar to that of endogenous PrP in these *Prn-p*^{+/0} mice (i.e., 0.5 × with respect to *Prn-p*^{+/+} mice), whereas the expression level of PrP^ΔCR in the B line was ~2-fold higher (1 ×).

Neurological symptoms of Tg(ΔCR) mice and amelioration by wild-type PrP

F1 offspring from all three founders that were hemizygous for the PrP^ΔCR transgene and heterozygous for the endogenous *Prn-p* gene became ill within 2 weeks of birth and died within 1 month (Table I; lines 1, 3, and 6). Symptoms in these neonatal animals included decreased body size and weight, immobility, difficulty righting, myoclonic spasms, and tremor.

By analogy to the case of Tg(PrP^ΔN) mice expressing N-terminally truncated PrP, we hypothesized that coexpression of wild-type PrP would ameliorate the symptoms in Tg(ΔCR) mice. To maintain the lines, we therefore bred the A, B, and E founders to Tga20 mice (Fischer *et al*, 1996), which overexpress wild-type PrP by five-fold when the transgene array is present in the hemizygous state. Tg(ΔCR-A^{+/0}) and

Table 1 Characteristics of Tg(Δ CR) mouse lines

	Genotype ^a	Onset ^b	Death ^b	PrP Δ CR (fold) ^c	Wild-type PrP (fold) ^c
1.	Δ CR-A ^{+ /0} <i>Prn-p</i> ^{+ /0}	11 \pm 3 (9)	24 \pm 3 (7)	0.5	0.5
2.	Δ CR-A ^{+ /0} <i>Prn-p</i> ^{+ /0} Tga20 ^{+ /0}	281 \pm 31 (8)	> 360 (6)	0.5	5.5
3.	Δ CR-B ^{+ /0} <i>Prn-p</i> ^{+ /0}	7 (1)	16 (1)	1.0	0.5
4.	Δ CR-B ^{+ /0} <i>Prn-p</i> ^{+ /0} Tga20 ^{+ /0}	43 (1)	240 (1)	1.0	5.5
5.	Δ CR-E ^{+ /0} <i>Prn-p</i> ^{0 /0}	4 \pm 1 (30)	6 \pm 2 (26)	0.5	0
6.	Δ CR-E ^{+ /0} <i>Prn-p</i> ^{+ /0}	12 \pm 2 (40)	25 \pm 2 (34)	0.5	0.5
7.	Δ CR-E ^{+ /0} <i>Prn-p</i> ^{+ /+}	17 \pm 2 (28)	48 \pm 16 (22)	0.5	1.0
8.	Δ CR-E ^{+ /0} <i>Prn-p</i> ^{0 /0} Tga20 ^{+ /0}	249 \pm 27 (8)	499 \pm 76 (6)	0.5	5.0
9.	Δ CR-E ^{+ /0} <i>Prn-p</i> ^{+ /0} Tga20 ^{+ /0}	279 \pm 36 (16)	588 \pm 57 (10)	0.5	5.5
10.	Δ CR-E ^{+ /0} <i>Prn-p</i> ^{+ /+} Tga20 ^{+ /0}	298 \pm 25 (9)	491 \pm 100 (7)	0.5	6.0

^aTransgenic lines were designated A, B, and E.

^bMean age in days \pm s.e.m., with the number of mice given in parentheses. The > symbol indicates that mice were still alive at the time of writing.

^cExpression relative to the amount of PrP in *Prn-p*^{+ /+} mice, as determined by Western blotting.

Tg(Δ CR-E^{+ /0}) mice on the Tga20^{+ /0}/PrP^{+ /0} background did not develop symptoms until \sim 280 days and survived more than 360 days (Table 1; lines 2 and 9). In contrast, only one Tg(Δ CR-B^{+ /0}) mouse was obtained on the Tga20^{+ /0}/PrP^{+ /0} background, and this mouse became ill at 43 days of age and did not produce offspring (Table 1; line 4). The earlier age of disease onset in Tg(Δ CR-B) mice correlates with the higher expression level of mutant PrP in this line (Figure 1B).

In a previous study, we found that Tg(WT-E1) mice, which express wild-type PrP from the moPrP.Xho vector at a level four-fold higher than endogenous PrP, never develop clinical symptoms (Chiesa *et al*, 1998). Tga20 mice also do not show spontaneous illness (Fischer *et al*, 1996). Thus, the neurological illness seen in Tg(Δ CR) mice is specifically related in a dose-dependent fashion to the presence of the PrP Δ CR protein.

To investigate quantitatively the relationship between clinical illness and wild-type PrP expression levels, we bred Tg(Δ CR)/Tga20^{+ /0}/PrP^{+ /0} mice from the E line to either *Prn-p*^{0 /0} or *Prn-p*^{+ /+} mice, to obtain Tg(Δ CR-E^{+ /0}) offspring expressing different amounts of wild-type PrP encoded by either the endogenous *Prn-p* gene or the Tga20 transgene. We found that development of symptoms in Tg(Δ CR) mice was inversely correlated with the expression level of wild-type PrP. Tg(Δ CR-E^{+ /0})/Tga20^{0 /0}/*Prn-p*^{0 /0} mice, which completely lack wild-type PrP, appeared runted and displayed righting difficulty and myoclonic spasms by 4 days after birth (Figure 2); these animals died within 1 week (Table 1; line 5). Coexpression of wild-type PrP ameliorated the phenotype in a dose-dependent fashion: one *Prn-p* allele (0.5 \times expression level) delayed death until 25 days (Table 1; line 6) and two *Prn-p* alleles (1 \times expression level) delayed death until 48 days (Table 1; line 7). The presence of one Tga20 allele either with or without a *Prn-p* allele, (5–6 \times expression level), delayed symptom onset to 250–300 days and allowed the mice to survive > 1 year (Table 1; lines 8–10) (Figure 2). Symptoms in older, clinically ill Tg(Δ CR-E^{+ /0})/Tga20^{+ /0} mice included coarse tremor, staggering gait, hind limb paresis, and difficulty righting.

Neuropathology in Tg(Δ CR) mice

Compared to non-transgenic littermates (Figure 3C), symptomatic mice expressing PrP Δ CR showed marked cerebellar




Figure 2 Clinical phenotype of Tg(Δ CR-E^{+ /0}) mice at 3 days of age. All mice were on the *Prn-p*^{0 /0} background. The Tg(Δ CR) mouse, which completely lacks wild-type PrP, is runted and immobile. In contrast, two Tg(Δ CR)/Tga20^{+ /0} mice, which express 5 \times the endogenous level of wild-type PrP, are healthy, similar to a non-transgenic *Prn-p*^{0 /0} mouse (non-Tg).

atrophy, with reduction in the thickness of the granule cell and molecular layers (Figure 3A). There was a dramatic decrease in the number and density of cerebellar granule cells (Figure 3, compare D to F). In contrast, Purkinje cell number was unaffected (Figure 3, compare G to I). Immunohistochemical staining for glial fibrillary acidic protein (GFAP) demonstrated gliosis and astrocytic hypertrophy, which were most prominent in the granule cell and molecular layers of the cerebellar cortex (Figure 3, compare J to L). Consistent with the clinical observations, overexpression of wild-type PrP from the Tga20 transgene completely rescued cerebellar atrophy, granule cell loss, and astrogliosis in Tg(Δ CR) mice at 25 days of age (Figure 3B, E, and K). Based on hematoxylin and eosin staining, there were no obvious neuropathological abnormalities in areas of the brain outside of the cerebellum (not shown). In a previous study, we did not observe any histological abnormalities in




Figure 3 Neuropathological changes in Tg(Δ CR) mice at 25 days of age. Cerebellar sections were prepared from mice of the following genotypes: Tg(Δ CR-E $^{+/0}$)/Prn-p $^{+/0}$ (A, D, G, J); Tg(Δ CR-E $^{+/0}$)/Prn-p $^{+/0}$ /Tga20 $^{+/0}$ (B, E, H, K); and Prn-p $^{+/0}$ (C, F, I, L). Sections were stained with hematoxylin and eosin (A–F), an antibody to calbindin (G–I), or an antibody to GFAP (J–L). Abbreviations in panel G are as follows: ML, molecular layer; PCL, Purkinje cell layer; GCL, granule cell layer. Scale bars = 1 mm (A–C); 50 μ m (D–F); 70 μ m (G–I); 25 μ m (J–L).

Tg(WT-E1) mice overexpressing wild-type PrP by four-fold (Chiesa *et al*, 1998).

To further explore the mechanism underlying neuronal degeneration in Tg(Δ CR) mice, brain sections of symptomatic Tg(Δ CR) mice were analyzed by TUNEL as well as by immunocytochemical staining with antibodies to activated caspase-3. Degenerating cerebellar granule cells were strongly TUNEL-positive (Figure 4A), and some cells also stained positively for activated caspase-3 (Figure 4D). Occasional TUNEL-positive cells were also observed in the hippocampus and neocortex, although loss of neurons in these regions was not obvious in hematoxylin- and eosin-stained sections (not shown). Introduction of the Tga20 transgene abrogated appearance of TUNEL- and caspase-3-positive neurons in the cerebellum (Figure 4B and E). Only very rare cells positive for these markers were observed in age-matched, non-transgenic littermates (Figure 4C and F). Taken together, these results indicate that expression of

PrP Δ CR causes granule neurons to degenerate via an apoptotic process that is abrogated by overexpression of wild-type PrP.

Radovanovic *et al* (2005) reported that mice expressing PrP Δ N and Dpl display a leukoencephalopathy characterized by vacuolar degeneration of white matter regions of the brain and spinal cord, accompanied by axonal loss and deterioration of myelin sheaths. We observed similar abnormalities in older, symptomatic Tg(Δ CR)/Tga20 $^{+/0}$ mice. Coarse vacuolation was seen in the cerebellar white matter (Figure 5A), as well as in white matter tracts of the spinal cord (Figure 5C). In semi-thin plastic sections of the spinal cord white matter from Tg(Δ CR)/Tga20 $^{+/0}$ mice, we observed extensive loss of myelinated axons, accompanied by the presence of large vacuoles and degeneration of myelin sheaths into condensed spheroid bodies (Figure 5E). Interestingly, these mice did not display significant cerebellar granule cell loss (Figure 5A). This result suggests that leukoencephalopathy and granule




Figure 4 Apoptosis of cerebellar granule neurons in Tg(Δ CR) mice at 25 days of age. Cerebellar sections were prepared from mice of the following genotypes: Tg(Δ CR-E $^{+/0}$)/Prn-p $^{+/0}$ (A, D); Tg(Δ CR-E $^{+/0}$)/Prn-p $^{+/0}$ /Tga20 $^{+/0}$ (B, E); and Prn-p $^{+/0}$ (C, F). Sections were stained with TUNEL (red) and DAPI (violet) (A–C) or with an antibody to activated caspase-3 (D–F). DAPI stains cell nuclei. The arrows in panel D indicate granule cells positive for activated caspase-3. Counts of caspase-3-immunoreactive cells in five contiguous 100 \times fields yielded the following results (mean \pm s.d.): 7.3 \pm 2.6 (Tg(Δ CR-E $^{+/0}$)/Prn-p $^{+/0}$, three animals); 0.5 \pm 0.5 (Tg(Δ CR-E $^{+/0}$)/Prn-p $^{+/0}$ /Tga20 $^{+/0}$, two animals); 0 (Prn-p $^{+/0}$, one animal). Scale bars = 20 μ m (A–C); 30 μ m (D–F).




Figure 5 Vacuolar degeneration in the white matter of older, symptomatic Tg(Δ CR)/Tga20 $^{+/0}$ mice. Paraffin sections (A–D) or semi-thin plastic sections (E, F) were prepared from the cerebella (A, B) or spinal cords (C–F) of ill Tg(Δ CR-E $^{+/0}$)/Prn-p $^{+/0}$ /Tga20 $^{+/0}$ mice at 397 days of age (A, C, E) and healthy Prn-p $^{+/0}$ /Tga20 $^{+/0}$ control mice (B, D, F) at 491 days of age. Paraffin sections were stained with hematoxylin and eosin, and plastic sections with toluidine blue. Scale bars = 100 μ m (A, B); 120 μ m (C, D); 20 μ m (E, F).

cell degeneration are independent processes that both contribute to clinical symptoms in Tg(Δ CR) mice, and that over-expression of wild-type PrP rescues granule cell apoptosis

more effectively than white matter degeneration. No white matter pathology was observed in Tga20 mice in the absence of the PrP Δ CR transgene (Figure 5B, D, and F).

Biochemical and cell biological properties of PrP Δ CR

We performed several experiments to determine whether abnormalities in the biochemical properties or cellular localization of PrP Δ CR could contribute to the phenotype of Tg(Δ CR) mice. For these experiments, we utilized Tg(Δ CR) mice that lacked wild-type PrP to allow selective antibody recognition of the mutant protein. Similar to wild-type PrP, PrP Δ CR displayed three major bands on Western blots, representing di-, mono-, and unglycosylated isoforms, with the diglycosylated form predominating (Figure 6A, lanes 1 and 3). Following treatment with PNGase F, wild-type PrP appeared as two bands of 30 and 19 kDa, representing unglycosylated versions of full-length PrP and the C1 fragment, respectively (Figure 6A, lane 4). The latter fragment is produced physiologically by cleavage at approximately residue 110 (Harris *et al*, 1993; Chen *et al*, 1995). In contrast, PNGase treatment of PrP Δ CR produced primarily a single band of 27 kDa, representing an unglycosylated version of the uncleaved protein (Figure 6A, lane 2). PrP Δ CR did not produce a fragment equivalent to C1, consistent with the absence of the cleavage site in the deleted protein. These results indicate that PrP Δ CR is glycosylated like wild-type PrP, and is therefore processed through the secretory pathway, although it is not subject to cleavage at the C1 site.

We tested whether PrP Δ CR in the brains of transgenic mice adopted any of the biochemical properties characteristic of PrP Sc , including detergent insolubility (assayed by ultracentrifugation) and protease resistance (assayed by treatment with proteinase K). We found that, like wild-type PrP, PrP Δ CR remained in the supernatant fraction after ultracentrifugation (Figure 6B), and was completely digested by concentrations of proteinase K as low as 2.5 μ g/ml (Figure 6C). Under the




Figure 6 PrP^{ΔCR} from the brains of Tg mice is normally glycosylated and is not detergent-insoluble or protease-resistant. Detergent lysates were prepared from the brains of Tg(Δ CR-E^{+/0})/Prn-p^{0/0} mice (lanes 1, 2, 5, 6, 14–18; indicated by Δ CR) or Prn-p^{+/0} mice (lanes 3, 4, 7, 8, 9–13; indicated by WT). (A) Samples were incubated with (lanes 2, 4; indicated by +) or without (lanes 1, 3; indicated by –) PNGase to remove N-linked oligosaccharides and were then Western blotted with anti-PrP antibody 8H4. Uncleaved forms of PrP^{ΔCR} and wild-type PrP are indicated, respectively, by the white arrowhead (lane 2) and black arrowhead (lane 4). The asterisk (lane 4) indicates the C1 fragment of wild-type PrP. PrP^{ΔCR} does not produce a C1 fragment, although a slightly larger band that may represent the equivalent of the C2 fragment is faintly visible (lane 2). (B) Samples were subjected to ultracentrifugation and PrP present in supernatants (lanes 5, 7; indicated by S) and pellets (lanes 6, 8; indicated by P) was detected by Western blotting. (C) Samples were incubated with the indicated amounts of proteinase K (in μ g/ml) for 30 min at 37°C. PrP was then detected by Western blotting.




Figure 7 The cellular distribution of PrP^{ΔCR} is similar to that of wild-type PrP. Cerebellar granule neurons cultured from postnatal day 3 mice (A–C) and cryostat sections of the cerebella of postnatal day 6 mice (D–F) were stained with anti-PrP antibody 8H4. Neurons in panels A–C were not permeabilized with detergent before staining. Mice had the following genotypes: Tg(Δ CR-E^{+/0})/Prn-p^{0/0} (A, D); Prn-p^{+/0} (B, E); and Prn-p^{0/0} (C, F). Scale bars = 10 μ m (A–C); 50 μ m (D–F). Abbreviations in panels D and E are as follows: EGCL, external granule cell layer; IGCL, internal granule cell layer.

same conditions, PrP^{Sc} from scrapie-infected brain as well as mutant PrP from the brains of Tg(PG14) mice is pelleted by ultracentrifugation and produces a protease-resistant fragment (PrP^{27–30}) after digestion with proteinase K (Chiesa *et al*, 1998; data not shown).

To analyze the localization of PrP^{ΔCR}, cerebellar granule neurons cultured from postnatal day 3 mouse pups were surface-stained with anti-PrP monoclonal antibody 8H4. PrP^{ΔCR} was found to be uniformly distributed on the surface of cell bodies and neurites, similar to wild-type PrP on neurons from Prn-p^{+/0} mice (Figure 7A and B). The distribution of PrP^{ΔCR} was also similar to that of wild-type PrP in

immunostained cryostat sections of the cerebellum from postnatal day 6 mice (Figure 7D and E). In both Tg(Δ CR) and Prn-p^{+/0} mice, PrP was present throughout the internal and external granule cell layers. There was no evidence for the presence of aggregates of PrP^{ΔCR}. The specificity of antibody staining was confirmed by the lack of signal on cultured granule neurons and brain sections from Prn-p^{0/0} mice (Figure 7C and F). The distribution of PrP in other brain regions, including the hippocampus and neocortex, was also similar in Tg(Δ CR) and Prn-p^{+/0} mice (data not shown).

Taken together, these results indicate that deletion of residues 105–125 did not induce PrP to acquire biochemical

properties of PrP^{Sc} and did not substantially alter its cellular or anatomical distribution.

Discussion

We have engineered transgenic mice that express a form of PrP deleted for a conserved block of 21 amino acids in the central region of the protein (residues 105–125). These mice spontaneously develop a highly lethal neurodegenerative illness that is reversed in a dose-dependent manner by coexpression of wild-type PrP. This phenotype is reminiscent of, but much more severe than, those described in mice that express PrP harboring larger deletions of the N-terminus ($\Delta 32-121$ and $\Delta 32-134$), and in mice that ectopically express Dpl in the CNS. Our results define the 105–125 region as a crucial determinant of the neurotoxic and neuroprotective activities of PrP. These data also suggest new models for the normal, biological function of PrP^C and how this function may be subverted to generate neurotoxic signals during prion infection.

A common mechanism of neurotoxicity

It was previously reported that mice expressing N-terminally deleted forms of PrP ($\Delta 32-121$ and $\Delta 32-134$, collectively referred to as PrP Δ N) developed a neurodegenerative phenotype that was rescued by coexpression of endogenous, wild-type PrP (Shmerling *et al*, 1998; Flechsig *et al*, 2003). A neurodegenerative illness was also produced by ectopic expression in the CNS of Dpl, a PrP paralog that resembles PrP Δ N, as it consists of a three-helix structure homologous to the C-terminal half of PrP without the flexible, N-terminal tail (Sakaguchi *et al*, 1996; Moore *et al*, 1999, 2001; Nishida *et al*, 1999; Rossi *et al*, 2001; Anderson *et al*, 2004). The Dpl phenotype was also abrogated by coexpression of wild-type PrP.

It seems very likely that the same molecular mechanism underlies the neurotoxicity of PrP Δ CR, PrP Δ N, and Dpl. All three proteins lack a portion of the flexible, N-terminal tail found in full-length PrP, and the toxicity of each is antagonized by coexpression of wild-type PrP. In addition, it was previously reported that mice expressing PrP molecules deleted from residue 32 through residue 80, 93, or 106 are normal, whereas mice expressing PrP molecules with deletions that extend to residue 121 or 134 display a neurodegenerative phenotype (Shmerling *et al*, 1998). Thus, it is likely that PrP residues 105–125 constitute a critical functional domain whose absence is responsible for the neurotoxicity of both PrP Δ CR and PrP Δ N, and that the absence of a homologous domain in Dpl underlies the pathogenicity of this protein as well.

PrP Δ CR, PrP Δ N, and Dpl also produce similar neuropathological effects in transgenic mice. All three of these proteins cause cerebellar atrophy and apoptosis of granule neurons (this work; Shmerling *et al*, 1998; Moore *et al*, 2001). Dpl and PrP Δ N also induce degeneration of cerebellar Purkinje cells when expression is directed to these cells (Flechsig *et al*, 2003; Anderson *et al*, 2004). Each of the proteins also produces a second kind of pathology: vacuolar degeneration of white matter. In the case of PrP Δ N and Dpl, granule cell death is selectively rescued by wild-type PrP expression in neurons and white matter degeneration by wild-type PrP expression in oligodendrocytes (Radovanovic *et al*, 2005).

This result suggests that the two pathologies are likely to represent independent toxic effects of the proteins. This conclusion is consistent with our observation that vacuolation in the white matter of the spinal cord and cerebellum is observed in clinically ill Tg(Δ CR)/Tga20^{+/0} mice in the absence of cerebellar granule cell loss.

Mutant forms of PrP can be toxic as a result of protein misfolding and aggregation, leading to altered cellular trafficking and deposition of protease-resistant aggregates in the CNS (Harris, 2003). In contrast, PrP Δ CR does not become detergent-insoluble or protease-resistant and it appears to undergo normal trafficking to the cell surface. PrP Δ N and Dpl also appear to have normal biochemical and cellular properties, to the extent that these have been characterized (Shmerling *et al*, 1998; Massimino *et al*, 2004). Thus, it is likely that PrP Δ CR, PrP Δ N, and Dpl act via a common neurotoxic mechanism that is independent of protein aggregation, and that is more likely to be related to an effect on the normal biological activity of PrP^C.

Why is PrP Δ CR so toxic?

A striking feature of our results is the greatly enhanced lethality of PrP Δ CR compared to PrP Δ N and Dpl (at equivalent expression levels) and the requirement for much higher levels of wild-type PrP to rescue the Tg(Δ CR) phenotype. For example, Tg(PrP $\Delta 32-134$)/*Prn-p*^{0/0} mice, which express the mutant protein at $\sim 2 \times$ endogenous levels (using the same promoter as in our Tg(Δ CR) mice), become ill at approximately 3–5 weeks of age and die at 2–6 months (Shmerling *et al*, 1998). A single *Prn-p* allele ($0.5 \times$ expression level) is sufficient to completely rescue the phenotype of these animals. Several lines of *Prn-p*^{0/0} mice that ectopically express Dpl in brain at levels likely to be similar to those of endogenous PrP become ill at 6–18 months of age (Sakaguchi *et al*, 1996; Moore *et al*, 1999; Rossi *et al*, 2001). Again, a single *Prn-p* allele completely abrogates the phenotype in these animals. In contrast, transgenic mice with $0.5 \times$ expression level of PrP Δ CR (four-fold less than PrP $\Delta 32-134$) become ill at a much younger age (4 days on the *Prn-p*^{0/0} background), and supraphysiological levels of wild-type PrP (5 and $6 \times$) ameliorate, but are not sufficient to completely rescue, the neurodegenerative phenotype.

The marked difference between the specific toxic activities of PrP Δ CR on the one hand and PrP Δ N/Dpl on the other is most consistent with a model in which these proteins have different affinities for a hypothetical receptor (Tr) that serves to transduce the toxic signal (Figure 8A–C). The strong dose dependence that characterizes wild-type PrP rescue of the neurodegenerative phenotype and the fact that much higher expression levels of wild-type PrP are required to reverse the illness of Tg(Δ CR) mice suggest that wild-type PrP acts by competing with PrP Δ CR/PrP Δ N/Dpl for binding to this hypothetical receptor, preventing delivery of the toxic signal (or perhaps promoting delivery of a protective or trophic signal; see below). In this scheme, PrP Δ CR would have a higher affinity for Tr than PrP Δ N or Dpl, thus accounting for the greater specific toxicity of PrP Δ CR. In addition, the affinity of wild-type PrP for Tr would be higher than that of PrP Δ N/Dpl, but lower than that of PrP Δ CR. Thus, endogenous levels of wild-type PrP would be sufficient to completely abrogate neurodegeneration in Tg(PrP Δ N) or Tg(Dpl) mice,




Figure 8 Model for the neurotoxicity of PrP Δ CR, PrP Δ N, and PrP106–126. The structured, C-terminal half of PrP is shown in green and the flexible, N-terminal tail as a blue line. The CR segment of PrP (residues 105–125) is shown as a red rectangle. Tr, hypothetical signal-transducing protein that normally generates a neuroprotective signal (solid pink), but which can assume an altered conformation (cross-hatched pink) that generates a neurotoxic signal. Two binding sites between PrP and Tr are shown, one involving the C-terminal half of PrP and the other CR segment of PrP. When both binding sites are occupied, Tr elicits a non-essential neuroprotective signal (A). When only the C-terminal site is occupied (as would be the case when the CR segment is absent), the transducer delivers a neurotoxic signal (B, C). The relative binding affinities of PrP for Tr are PrP Δ CR > wild-type PrP > PrP Δ N. Thus, wild-type PrP can reverse the neurotoxicity of both PrP Δ CR and PrP Δ N by competing with them for binding to Tr, but PrP Δ CR requires supraphysiological levels of wild-type PrP. Dpl presumably binds to Tr with an affinity similar to that of PrP Δ N. In (D), the purple rectangle represents the synthetic peptide PrP106–126, which competes for binding of the CR segment of PrP to Tr. This elicits a neurotoxic signal similar to that produced by PrP Δ CR and PrP Δ N, but only in the presence of PrP.

but supraphysiological levels would be required to significantly delay illness in Tg(ACR) mice.

Functional and structural roles of the 105–125 region

How does deletion of residues 105–125 alter the biological activity of PrP in such a dramatic way? Five of the first six amino acids of this segment are polar, including three positively charged residues, whereas the last 15 amino acids are all hydrophobic (Figure 1A). Strikingly, the 105–125 region of PrP is the most evolutionarily conserved part of the protein, with the positively charged residues and the hydrophobic stretch present in PrP homologs from fish to humans (Rivera-Milla *et al*, 2006). It is therefore likely that this segment participates in an essential biological function of the protein.

Residues 105–125 lie within a region that plays an important role in determining the membrane topology of PrP. Residues 111–135 constitute a hydrophobic domain that can span the lipid bilayer in transmembrane forms of PrP (CtmPrP and NtmPrP) (Hegde *et al*, 1998; Stewart *et al*, 2001), whereas residues 103–111 function as a ‘stop transfer effector’ (STE) that regulates membrane insertion of the adjacent hydrophobic segment (Yost *et al*, 1990) (Figure 1A). Whether the toxicity of PrP Δ CR (as well as PrP Δ N and Dpl) results from impaired ability of these proteins to adopt a transmembrane topology remains to be determined. The hydrophobic domain of PrP has also been implicated in sorting of the protein in polarized cells (Uelhoff *et al*, 2005) and in binding to certain ligands (Zanata *et al*, 2002), functions that might also play a role in the toxicity of PrP Δ CR.

Based on NMR analysis of recombinant and brain-derived PrP, residues 23–125 form a relatively unstructured,

N-terminal tail, whereas residues 128–230 constitute a folded domain comprised of three α -helices and two short β -strands flanking helix 1 (Zahn *et al*, 2000; Hornemann *et al*, 2004). Because residues 105–125 lie within the flexible tail, their deletion would not be expected to dramatically alter the C-terminal, folded domain of PrP (Zahn *et al*, 2000). These considerations suggest that the toxicity of PrP Δ CR results from elimination of a critical binding site encompassing residues 105–125 within the flexible tail (Figure 8), rather than from significant structural alterations induced in the C-terminal half of the molecule. As both PrP Δ N and PrP Δ CR are missing the 105–125 region, the enhanced lethality of the latter must presumably be due to additional binding interactions between PrP Δ CR and Tr involving residues 32–104.

Neuroprotective and neurotoxic effects of PrP

Paradoxically, PrP has been reported to play a role in both neurotoxic and neuroprotective phenomena (Harris and True, 2006). On the one hand, PrP^C can protect cells from several kinds of pro-apoptotic stimuli (Kuwahara *et al*, 1999; Bounhar *et al*, 2001; Brown *et al*, 2002; Diarra-Mehrpour *et al*, 2004; McLennan *et al*, 2004; Li and Harris, 2005; Roucou *et al*, 2005; Spudich *et al*, 2005). Conversely, PrP promotes cell death in some experimental situations (Brown *et al*, 1994; Solforosi *et al*, 2004; Sunyach and Checler, 2005).

The phenotype of Tg(PrP Δ CR) and Tg(PrP Δ N) mice exemplifies the opposing neuroprotective and neurotoxic activities of PrP, as wild-type PrP exhibits a protective effect against the toxic effect of mutant PrP. Our results with Tg(Δ CR) mice suggest that residues 105–125 are essential for eliciting the neuroprotective activity of PrP, and that

deletion of this segment converts PrP from a neuroprotective into a neurotoxic molecule. In terms of the model presented above, we hypothesize that PrP^C binding to the hypothetical receptor, Tr, normally delivers a neuroprotective signal (Figure 8A). This signal would have to be non-essential, as PrP-null mice display a relatively normal phenotype (Büeler *et al*, 1992; Manson *et al*, 1994). We postulate that deletion of residues 105–125 alters or subverts the interaction between PrP and Tr in such a way that a neurotoxic rather than a neuroprotective signal is produced (Figure 8B and C). This subversion of activity might occur because delivery of a neuroprotective signal requires that PrP bind to Tr at two distinct sites: the 105–125 region and the structured, C-terminal domain. Binding to the C-terminal domain alone, in the absence of binding to the 105–125 region, might produce a neurotoxic rather than a neuroprotective signal. The change from neuroprotective to neurotoxic signaling presumably involves a conformational alteration in Tr.

The model outlined here is different from that previously proposed to explain the neurotoxicity of PrP^{ΔN} and Dpl (Shmerling *et al*, 1998). The latter model, which is based on a loss rather than a subversion of function, postulates the existence of two hypothetical molecules, one of which is a ligand that binds to PrP and the other a receptor that binds the ligand when PrP is absent.

A possible mechanism for the toxicity of PrP^{106–126} and PrP^{Sc}

It is striking that a synthetic peptide comprising human PrP residues 106–126 (equivalent to residues 105–125 in murine PrP, the region deleted in PrP^{ΔCR}) has been reported to be toxic to neurons cultured from *Prn-p*^{+/+} but not *Prn-p*^{0/0} mice (Forloni *et al*, 1993; Brown *et al*, 1994; Fioriti *et al*, 2005). This result suggests the hypothesis that the peptide alters interaction between PrP and the hypothetical transducer Tr by competitively blocking binding within the 105–125 region of PrP (Figure 8D). This would then produce a toxic signal equivalent to the one elicited by PrP^{ΔCR}, which lacks the 105–125 domain. In the absence of PrP^C, no signal would be delivered and the peptide would have no effect.

A similar mechanism could be invoked to explain the toxic effect of PrP^{Sc}, which also appears to require expression of PrP^C (Brandner *et al*, 1996; Mallucci *et al*, 2003). In this case, PrP^{Sc} might perturb interaction between PrP^C and Tr by blocking binding within the 105–125 domain, thereby producing a toxic signal equivalent to the one elicited PrP^{ΔCR} and by PrP^{106–126}. Consistent with this model, PrP^{106–126} displays certain biochemical properties typical of PrP^{Sc} (aggregation, protease resistance), and its mechanism of toxicity has been proposed to be similar to that of PrP^{Sc} (Selvaggi *et al*, 1993). In addition, PrP^{Sc} appears to be conformationally altered in the 105–125 region (Peretz *et al*, 1997).

Future studies

The work presented here identifies residues 105–125 as a critical functional domain of PrP whose deletion endows the protein with powerful neurotoxic properties. To further elucidate the molecular basis of this effect, it will be necessary to identify other proteins, such as the hypothetical receptor Tr, that play a role in transducing the neurotoxic and neuroprotective signals that emanate from PrP. As PrP^{ΔCR} appears to engage the signal transducing machinery with very high

affinity, it may facilitate discovery of PrP-interacting proteins using biochemical methods. The enhanced toxic potency of PrP^{ΔCR} may also allow the development of improved cell culture models to analyze the signaling pathways activated by PrP. Thus far, there has been only limited success in reproducing the toxic effects of PrP^{ΔN} and Dpl in cultured cells (Drisaldi *et al*, 2004). Finally, it will be of great interest to further explore the relationship between the neurotoxic pathways activated by PrP^{Sc} and PrP^{ΔCR}, and to determine whether common mechanisms are involved.

Materials and methods

Production of transgenic mice

A cDNA encoding murine PrP^{ΔCR} (PrP^{105–125}) was generated by preparing the 5' and 3' halves of the cDNA separately, and then introducing these into the cloning vector in a three-part ligation reaction. The 5' half of the cDNA was amplified by PCR using as a template pcDNA3 containing wild-type mouse PrP with a 3F4 epitope tag (Lehmann and Harris, 1995). The upstream primer was Tg51 (5'-GTACAGGACCAAGCTTAGTCTCGAGCCATGGCGAACCTTGCTACTGGCTGCTG-3') and the downstream primer was Tg31 (5'-GCTCATGGCGCTCCCAGCATGTAGCTGGTTGCTGGGCTGTTCACCTGATT-3'). Primer Tg51 contained a *Hind*III restriction site and primer Tg31 contained the 104–126 junction sequence and an *Hae*II restriction site. The resulting PCR product was digested with *Hind*III and *Hae*II. A fragment encoding the 3' half of PrP^{ΔCR} was generated by digesting wild-type mouse PrP/pcDNA3 with *Hae*II and *Bam*HI. The 5' and 3' halves of the PrP^{ΔCR} cDNA were then ligated into pcDNA3.1(+) (Invitrogen, Carlsbad, CA). A fragment encoding the complete PrP^{ΔCR} sequence was then released from the resulting plasmid by digestion with *Hind*III/*Bam*HI, and blunted by treatment with Klenow polymerase. The blunted fragment was then ligated into transgenic expression vector MoPrP.Xho (Borchelt *et al*, 1996) that had been cleaved with *Xho*I and then blunted. Recombinant plasmid with the insert in the correct orientation was selected by *Eco*RI digestion and sequencing. The transgene was excised from the recombinant plasmid by digestion with *Not*I, purified on GFX PCR DNA purification columns (Amersham Biosciences), and injected into the pronuclei of fertilized eggs from an F₂ cross of C57BL/6J × CBA/J F₁ parental mice.

Transgenic founders were bred to the following mouse strains: C57BL/6J × CBA/J parental mice; *Prn-p*^{0/0} mice obtained from Charles Weissmann that had been produced on a 129 × C57BL/6J background (Büeler *et al*, 1992); or Tga20 mice (Fischer *et al*, 1996) to maintain the lines.

Mice were genotyped by PCR analysis of tail DNA prepared using the Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN). The primer pairs used were as follows: P1 and P4 (Chiesa *et al*, 1998) which amplify both the PrP^{ΔCR} and Tga20 transgenes; ΔCR (5'-CCTCGAAGCTTAGTCTCGAGCC-3') and E4 (5'-TCATGGC GCTCCCAGCATGTA-3'), which amplify only the PrP^{ΔCR} transgene; and P2 and P4 (Chiesa *et al*, 1998) which amplify the *Prn-p*⁺ and *Prn-p*⁰ alleles.

Histology

Animals were perfusion-fixed and paraffin sections of brain and spinal cord were stained with hematoxylin and eosin or with anti-GFAP antibodies as described previously (Chiesa *et al*, 1998), except that GFAP antibodies were visualized using AlexaFluor 594-coupled goat anti-rabbit IgG (Invitrogen). Purkinje cells were visualized by staining sections with a rabbit antibody to calbindin (Chemicon, Temecula, CA), followed by visualization with AlexaFluor 488-coupled goat anti-rabbit IgG (Invitrogen).

For TUNEL, paraffin sections prepared as above were treated in permeabilization solution (0.1M citrate buffer, pH 6.0, 0.05% Tween 20) and labeled with *In Situ* Cell Death Detection Kit according to the manufacturer's protocol (Roche Diagnostics, Indianapolis, IN). Caspase-3 activation was monitored using an anti-activated caspase-3 antibody (Cell Signaling Technology, Beverly, MA) and visualized using the peroxidase-anti-peroxidase method as described previously (Young *et al*, 2005). Sections were stained with either DAPI or hematoxylin to visualize cell nuclei.

For PrP immunohistochemistry, brains were immersion-fixed and then 14 μ m sagittal sections were cut with a cryostat. Sections were pretreated in PBS containing 0.2% Triton X-100 for 30 min at room temperature. Staining was performed using anti-PrP monoclonal antibody 8H4 (Zanusso *et al*, 1998), followed by visualization using AlexaFluor 488-coupled goat anti-mouse IgG.

For preparation of semi-thin plastic sections, mice were perfusion-fixed with ice-cold 4% paraformaldehyde/3% glutaraldehyde and spinal cords were embedded in Epon. One micron sections were cut and stained with toluidine blue for viewing by light microscopy.

Biochemical assays

Detergent insolubility and protease resistance of PrP in postnuclear supernatants of brain were assayed as described previously (Chiesa *et al*, 1998). To deglycosylate PrP, postnuclear supernatants were treated with PNGase F according to the manufacturer's instructions (New England Biolabs, Beverly, MA). Samples were analyzed by Western blotting using anti-PrP antibody 8H4 with the ECL detection system (Amersham Biosciences, Piscataway, NJ).

References

- Aguzzi A, Polymenidou M (2004) Mammalian prion biology: one century of evolving concepts. *Cell* **116**: 313–327
- Anderson L, Rossi D, Linehan J, Brandner S, Weissmann C (2004) Transgene-driven expression of the Doppel protein in Purkinje cells causes Purkinje cell degeneration and motor impairment. *Proc Natl Acad Sci USA* **101**: 3644–3649
- Borchelt DR, Davis J, Fischer M, Lee MK, Slunt HH, Ratovitsky T, Regard J, Copeland NG, Jenkins NA, Sisodia SS, Price DL (1996) A vector for expressing foreign genes in the brains and hearts of transgenic mice. *Genet Anal Biomol Eng* **13**: 159–163
- Bounhar Y, Zhang Y, Goodyer CG, LeBlanc A (2001) Prion protein protects human neurons against Bax-mediated apoptosis. *J Biol Chem* **276**: 39145–39149
- Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A (1996) Normal host prion protein necessary for scrapie-induced neurotoxicity. *Nature* **379**: 339–343
- Brown DR, Herms J, Kretzschmar HA (1994) Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment. *NeuroReport* **5**: 2057–2060
- Brown DR, Nicholas RS, Canevari L (2002) Lack of prion protein expression results in a neuronal phenotype sensitive to stress. *J Neurosci Res* **67**: 211–224
- Büeler H, Fischer M, Lang Y, Fluethmann H, Lipp H-P, DeArmond SJ, Prusiner SB, Aguet M, Weissmann C (1992) Normal development and behavior of mice lacking the neuronal cell-surface PrP protein. *Nature* **356**: 577–582
- Chen SG, Teplow DB, Parchi P, Teller JK, Gambetti P, Autiliogambetti L (1995) Truncated forms of the human prion protein in normal brain and in prion diseases. *J Biol Chem* **270**: 19173–19180
- Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, Oldstone M (2005) Anchorless prion protein results in infectious amyloid disease without clinical scrapie. *Science* **308**: 1435–1439
- Chiesa R, Piccardo P, Ghetti B, Harris DA (1998) Neurological illness in transgenic mice expressing a prion protein with an insertional mutation. *Neuron* **21**: 1339–1351
- Diarra-Mehrpour M, Arrabal S, Jalil A, Pinson X, Gaudin C, Pietu G, Pitaval A, Ripoche H, Eloit M, Dormont D, Chouaib S (2004) Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. *Cancer Res* **64**: 719–727
- Drisaldi B, Coomaraswamy J, Mastrangelo P, Strome B, Yang J, Watts JC, Chishti MA, Marvi M, Windl O, Ahrens R, Major F, Sy MS, Kretzschmar H, Fraser PE, Mount HT, Westaway D (2004) Genetic mapping of activity determinants within cellular prion proteins: N-terminal modules in PrP^C offset pro-apoptotic activity of the Doppel helix B/B' region. *J Biol Chem* **279**: 55443–55454
- Fioriti L, Quaglio E, Massignan T, Colombo L, Stewart RS, Salmona M, Harris DA, Forloni G, Chiesa R (2005) The neurotoxicity of prion protein (PrP) peptide 106-126 is independent of the expression level of PrP and is not mediated by abnormal PrP species. *Mol Cell Neurosci* **28**: 165–176
- Fischer M, Rüllicke T, Raeber A, Sailer A, Moser M, Oesch B, Brandner S, Aguzzi A, Weissmann C (1996) Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. *EMBO J* **15**: 1255–1264
- Flechsig E, Hegyi I, Leimerth R, Zuniga A, Rossi D, Cozzio A, Schwarz P, Rulicke T, Gotz J, Aguzzi A, Weissmann C (2003) Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. *EMBO J* **22**: 3095–3101
- Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F (1993) Neurotoxicity of a prion protein fragment. *Nature* **362**: 543–546
- Harris DA (2003) Trafficking, turnover and membrane topology of PrP. *Br Med Bull* **66**: 71–85
- Harris DA, Huber MT, van Dijken P, Shyng S-L, Chait BT, Wang R (1993) Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. *Biochemistry* **32**: 1009–1016
- Harris DA, True HL (2006) New insights into prion structure and toxicity. *Neuron* **50**: 353–357
- Hegde RS, Mastroianni JA, Scott MR, Defea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR (1998) A transmembrane form of the prion protein in neurodegenerative disease. *Science* **279**: 827–834
- Hornemann S, Schorn C, Wuthrich K (2004) NMR structure of the bovine prion protein isolated from healthy calf brains. *EMBO Rep* **5**: 1159–1164
- Hoshino S, Inoue K, Yokoyama T, Kobayashi S, Asakura T, Teramoto A, Itoharu S (2003) Prions prevent brain damage after experimental brain injury: a preliminary report. *Acta Neurochir Suppl* **86**: 297–299
- Kuwahara C, Takeuchi AM, Nishimura T, Haraguchi K, Kubosaki A, Matsumoto Y, Saeki K, Yokoyama T, Itoharu S, Onodera T (1999) Prions prevent neuronal cell-line death. *Nature* **400**: 225–226
- Lehmann S, Harris DA (1995) A mutant prion protein displays an aberrant membrane association when expressed in cultured cells. *J Biol Chem* **270**: 24589–24597
- Li A, Harris DA (2005) Mammalian prion protein suppresses Bax-induced cell death in yeast. *J Biol Chem* **280**: 17430–17434
- Li A, Sakaguchi S, Atarashi R, Roy BC, Nakaoko R, Arima K, Okimura N, Kopacek J, Shigematsu K (2000) Identification of a novel gene encoding a PrP-like protein expressed as chimeric transcripts fused to PrP exon 1/2 in ataxic mouse line with a disrupted PrP gene. *Cell Mol Neurobiol* **20**: 553–567
- Luhers T, Riek R, Guntert P, Wuthrich K (2003) NMR structure of the human doppel protein. *J Mol Biol* **326**: 1549–1557
- Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J (2003) Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. *Science* **302**: 871–874

- Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J (1994) 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. *Mol Neurobiol* **8**: 121–127
- Massimino ML, Ballarin C, Bertoli A, Casonato S, Genovesi S, Negro A, Sorgato MC (2004) Human Doppel and prion protein share common membrane microdomains and internalization pathways. *Int J Biochem Cell Biol* **36**: 2016–2031
- McLennan NF, Brennan PM, McNeill A, Davies I, Fotheringham A, Rennison KA, Ritchie D, Brannan F, Head MW, Ironside JW, Williams A, Bell JE (2004) Prion protein accumulation and neuroprotection in hypoxic brain damage. *Am J Pathol* **165**: 227–235
- Miller TM, Johnson Jr EM (1996) Metabolic and genetic analyses of apoptosis in potassium/serum-deprived rat cerebellar granule cells. *J Neurosci* **16**: 7487–7495
- Mo H, Moore RC, Cohen FE, Westaway D, Prusiner SB, Wright PE, Dyson HJ (2001) Two different neurodegenerative diseases caused by proteins with similar structures. *Proc Natl Acad Sci USA* **98**: 2352–2357
- Moore RC, Lee IY, Silverman GL, Harrison PM, Strome R, Heinrich C, Karunaratne A, Pasternak SH, Chishti MA, Liang Y, Mastrangelo P, Wang K, Smit AF, Katamine S, Carlson GA, Cohen FE, Prusiner SB, Melton DW, Tremblay P, Hood LE, Westaway D (1999) Ataxia in prion protein (PrP)-deficient mice is associated with upregulation of the novel PrP-like protein doppel. *J Mol Biol* **292**: 797–817
- Moore RC, Mastrangelo P, Bouzamondo E, Heinrich C, Legname G, Prusiner SB, Hood L, Westaway D, DeArmond SJ, Tremblay P (2001) Doppel-induced cerebellar degeneration in transgenic mice. *Proc Natl Acad Sci USA* **98**: 15288–15293
- Nishida N, Tremblay P, Sugimoto T, Shigematsu K, Shirabe S, Petromilli C, Erpel SP, Nakaoka R, Atarashi R, Houtani T, Torchia M, Sakaguchi S, DeArmond SJ, Prusiner SB, Katamine S (1999) A mouse prion protein transgene rescues mice deficient for the prion protein gene from Purkinje cell degeneration and demyelination. *Lab Invest* **79**: 689–697
- Peretz D, Williamson RA, Matsunaga Y, Serban H, Pinilla C, Bastidas RB, Rozenshteyn R, James TL, Houghten RA, Cohen FE, Prusiner SB, Burton DR (1997) A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoform. *J Mol Biol* **273**: 614–622
- Prusiner SB (1998) Prions. *Proc Natl Acad Sci USA* **95**: 13363–13383
- Radovanovic I, Braun N, Giger OT, Mertz K, Miele G, Prinz M, Navarro B, Aguzzi A (2005) Truncated prion protein and Doppel are myelinotoxic in the absence of oligodendrocytic PrP^C. *J Neurosci* **25**: 4879–4888
- Rivera-Milla E, Oidtmann B, Panagiotidis CH, Baier M, Sklaviadis T, Hoffmann R, Zhou Y, Solis GP, Stuermer CA, Malaga-Trillo E (2006) Disparate evolution of prion protein domains and the distinct origin of Doppel- and prion-related loci revealed by fish-to-mammal comparisons. *FASEB J* **20**: 317–319
- Rossi D, Cozzio A, Flechsig E, Klein MA, Rulicke T, Aguzzi A, Weissmann C (2001) Onset of ataxia and Purkinje cell loss in PrP null mice inversely correlated with Dpl level in brain. *EMBO J* **20**: 694–702
- Roucou X, Giannopoulos PN, Zhang Y, Jodoin J, Goodyer CG, LeBlanc A (2005) Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells. *Cell Death Differ* **12**: 783–795
- Roucou X, LeBlanc AC (2005) Cellular prion protein neuroprotective function: implications in prion diseases. *J Mol Med* **83**: 3–11
- Sakaguchi S, Katamine S, Nishida N, Moriuchi R, Shigematsu K, Sugimoto T, Nakatani A, Kataoka Y, Houtani T, Shirabe S, Okada H, Hasegawa S, Miyamoto T, Noda T (1996) Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted PrP gene. *Nature* **380**: 528–531
- Selvaggini C, De Gioia L, Cantu L, Ghibaudi E, Diomedea L, Passerini F, Forloni G, Bugiani O, Tagliavini F, Salmona M (1993) Molecular characteristics of a protease-resistant, amyloidogenic and neurotoxic peptide homologous to residues 106–126 of the prion protein. *Biochem Biophys Res Commun* **194**: 1380–1386
- Shmerling D, Hegyi I, Fischer M, Blättler T, Brandner S, Götz J, Rüllicke T, Flechsig E, Cozzio A, von Mering C, Hangartner C, Aguzzi A, Weissmann C (1998) Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. *Cell* **93**: 203–214
- Solforosi L, Criado JR, McGavern DB, Wirz S, Sanchez-Alavez M, Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E, Gilden D, Oldstone MB, Conti B, Williamson RA (2004) Cross-linking cellular prion protein triggers neuronal apoptosis *in vivo*. *Science* **303**: 1514–1516
- Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, Bassetti CL, Hermann DM (2005) Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1. *Neurobiol Dis* **20**: 442–449
- Stewart RS, Drisaldi B, Harris DA (2001) A transmembrane form of the prion protein contains an uncleaved signal peptide and is retained in the endoplasmic reticulum. *Mol Biol Cell* **12**: 881–889
- Sunyach C, Checler F (2005) Combined pharmacological, mutational and cell biology approaches indicate that p53-dependent caspase 3 activation triggered by cellular prion is dependent on its endocytosis. *J Neurochem* **92**: 1399–1407
- Uelhoff A, Tatzelt J, Aguzzi A, Winkelhofer KF, Haass C (2005) A pathogenic PrP mutation and doppel interfere with polarized sorting of the prion protein. *J Biol Chem* **280**: 5137–5140
- Yost CS, Lopez CD, Prusiner SB, Myers RM, Lingappa VR (1990) Non-hydrophobic extracytoplasmic determinant of stop transfer in the prion protein. *Nature* **343**: 669–672
- Young C, Roth KA, Klocke BJ, West T, Holtzman DM, Labruyere J, Qin YQ, Dikranian K, Olney JW (2005) Role of caspase-3 in ethanol-induced developmental neurodegeneration. *Neurobiol Dis* **20**: 608–614
- Zahn R, Liu A, Luhrs T, Riek R, von Schroetter C, Lopez Garcia F, Billeter M, Calzolari L, Wider G, Wüthrich K (2000) NMR solution structure of the human prion protein. *Proc Natl Acad Sci USA* **97**: 145–150
- Zanata SM, Lopes MH, Mercadante AF, Hajj GN, Chiarini LB, Nomizo R, Freitas AR, Cabral AL, Lee KS, Juliano MA, de Oliveira E, Jachieri SG, Burlingame A, Huang L, Linden R, Brentani RR, Martins VR (2002) Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. *EMBO J* **21**: 3307–3316
- Zanusso G, Liu D, Ferrari S, Hegyi I, Yin X, Aguzzi A, Hornemann S, Liemann S, Glockshuber R, Manson JC, Brown P, Petersen RB, Gambetti P, Sy MS (1998) Prion protein expression in different species: analysis with a panel of new mAbs. *Proc Natl Acad Sci USA* **95**: 8812–8816